Karakteristik Pasien Systemic Lupus Erythematosus di Rumah Sakit Ibnu Sina Makassar 2020–2023
Article Sidebar
Main Article Content
Abstract
Systemic Lupus Erythematosus (SLE) merupakan penyakit autoimun kronis dengan manifestasi klinis dan komplikasi yang beragam, sehingga pemetaan karakteristik pasien diperlukan untuk mendukung deteksi dini dan penatalaksanaan. Penelitian ini bertujuan mengetahui karakteristik pasien SLE di Rumah Sakit Ibnu Sina YW-UMI Makassar periode 2020–2023. Penelitian menggunakan desain deskriptif dengan data sekunder rekam medis dan teknik total sampling. Sampel penelitian berjumlah 18 pasien yang memenuhi kriteria. Variabel yang dianalisis meliputi jenis kelamin, usia, manifestasi klinis, komplikasi, riwayat terapi, dan riwayat keluarga SLE. Hasil penelitian menunjukkan seluruh pasien berjenis kelamin perempuan (100,00%); kelompok usia terbanyak >40 tahun (66,66%); manifestasi klinis tersering adalah muskuloskeletal (50,0%); komplikasi tersering adalah nefritis lupus (27,77%); terapi yang paling banyak digunakan adalah kombinasi imunosupresan dan kortikosteroid (55,56%); dan mayoritas pasien tidak memiliki riwayat keluarga SLE (66,66%). Disimpulkan bahwa pasien SLE pada periode penelitian didominasi perempuan usia >40 tahun dengan manifestasi muskuloskeletal, komplikasi nefritis lupus, serta penggunaan terapi kombinasi imunosupresan-kortikosteroid.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All rights reserved. This publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording.
References
Ahmed, A., Sultan, M. O., Khan, M. I., & Ahmed, A. (2025). Clinical and Immunological Manifestations of Patients Presenting With Systemic Lupus Erythematosus At Tertiary Care Hospital, Karachi. Biological and Clinical Sciences Research Journal, 6(1), 83–87. https://doi.org/10.54112/bcsrj.v6i1.1545
Aishah, N., Salihin, N. M., Majdiah, W., Mohamad, W., Balqees, A., Thaha, M., Arif, M., Nawi, A., Jazman, M., & Rahim, C. (2025). Association between disease activity and clinico-laboratory parameters in Systemic Lupus Erythematosus patients in Hospital Universiti Sains Malaysia: a retrospective study. IIUM Journal of Orofacial and Health Sciences, 6(1), 41–49. https://doi.org/10.31436/ijoh
Alanazi, W. (2024). International Journal of Clinical Rheumatology Demographics and Clinical Manifestations of Lupus patients: Experience from a Private Hospital. https://doi.org/10.37532/1758-4272.2024.19(5).60-64
Alhassan, N., Almetri, T., Abualsoud, S., Malhis, A., Al-Qahtani, K., Alwazna, A., Salloum, N., Zaeri, B., Hegazy, A., Mohamed, S., Bashawri, Y., & Al Ghanim, N. (2021). Causes of Hospitalization for Systemic Lupus Erythematosus in Saudi Arabia Compared With the Global Setting: A Retrospective Single-center Observational Study. Cureus. https://doi.org/10.7759/cureus.18858
AlOmair, M., AlMalki, H., AlShahrani, M., Mushait, H., Al Qout, M., Alshehri, T., AlAlyani, R., Algarni, A., Almaker, Y., & Madkli, E. (2023). Clinical Manifestations of Systemic Lupus Erythematosus in a Tertiary Center in Saudi Arabia. Cureus. https://doi.org/10.7759/cureus.41215
Emorinken, A., Dic-Ijiewere, M. O., Erameh, C. O., Ugheoke, A. J., Agbadaola, O. R., & Agbebaku, F. O. (2021). Clinical and laboratory profile of systemic lupus erythematosus patients at a rural tertiary centre in South-South Nigeria: Experience from a new rheumatology clinic. Reumatologia, 59(6), 402–410. https://doi.org/10.5114/reum.2021.111714
Fatmawati, A. (2018). REGULASI DIRI PADA PENYAKIT KRONIS - SYSTEMIC LUPUS ERYTHEMATOSUS : KAJIAN LITERATUR. Jurnal Keperawatan Indonesia, 21(1), 43–50. https://doi.org/10.7454/jki.v21i1.542
Gutbi, H. A., Elagib, E. M., Essa, M. E. A., Ahmed, N. I., & Saadelnour, M. A. I. (2022). Pattern and clinical phenotype of systemic lupus erythematosus among male patients: Hospital-based study. Clinical and Translational Discovery, 2(4). https://doi.org/10.1002/ctd2.148
Hamijoyo, L., Candrianita, S., Rahmadi, A. R., Dewi, S., Darmawan, G., Suryajaya, B. S., Rainy, N. R., Hidayat, I. I., Moenardi, V. N., & Wachjudi, R. G. (2019). The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. Lupus, 28(13), 1604–1609. https://doi.org/10.1177/0961203319878499
Hamijoyo, L., Sahiratmadja, E., Ghassani, N. G., Darmawan, G., Susandi, E., Van Crevel, R., Hill, P. C., & Alisjahbana, B. (2022). Tuberculosis among Patients with Systemic Lupus Erythematosus in Indonesia: A Cohort Study. Open Forum Infectious Diseases, 9(7). https://doi.org/10.1093/ofid/ofac201
Islam, R., Dey, A., & Mahmud, E. (2025). Peer Review Process: The Journal “The Journal of Teachers Association” abides Hospital. Journal of Teachers Association, 38(2), 208–214. https://doi.org/10.70818/taj.v38i02.0270
Khalil, N. K., Alenzi, F., Omair, M. A., Almaghlouth, I., Altuwaijri, M., Barri, M., Alqahtani, R. M., Alrabiah, A., & Alhijji, A. (2023). An Examination of Infection Incidence and Management in Systemic Lupus Erythematosus Patients: A Five-Year Review from a Saudi Arabian Center. Medical Science Monitor, 29. https://doi.org/10.12659/MSM.941277
Marri, L., Vassallo, C., Esposito, P., Bottaro, L., De Palma, R., & Negrini, S. (2024). Clinical Characteristics of Systemic Lupus Erythematosus in Caucasians and Latin American Hispanics: Data from a Single Tertiary Center. Autoimmune Diseases, 2024. https://doi.org/10.1155/2024/5593302
Odunlami, G. J., Ajibade, A., Omotoso, B. A., Hassan, M. O., Adefidipe, A. A., Olanrewaju, F. O., Enitan, A. O., Adetunji, T. A., Akinyele, O. A., & Okunola, O. (2024). Clinical and laboratory profiles of systemic lupus erythematosus patients in a new rheumatology clinic in southwestern Nigeria. Reumatologia, 62(2), 83–93. https://doi.org/10.5114/reum/187208
Werth, V. P., Merola, J. F., Wenzel, J., Delev, N., Kothari, H., Meier, R., Singhal, S., Madireddi, M., & Korish, S. (2023). AB0609 DESIGN OF A PHASE 2, DOUBLE-BLIND, Placebo-Controlled, Global Trial Of Deucravacitinib, An Oral, Selective, Allosteric Tyrosine Kinase 2 (Tyk2) Inhibitor, In Patients With Active Discoid And/Or Subacute Cutaneous Lupus Erythematosus. 1506.1-1506. https://doi.org/10.1136/annrheumdis-2023-eular.1712